Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 19/20 | 0.86 |
| ▸ | CDK2 | P24941 | 9/20 | 0.86 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.86 |
| ▸ | ABL1 | P00519 | 4/20 | 0.86 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.86 |
| ▸ | RET | P07949 | 3/20 | 0.86 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.86 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.86 |
| ▸ | BCR | P11274 | 3/20 | 0.86 |
| ▸ | PLK4 | O00444 | 2/20 | 0.86 |
| ▸ | JAK2 | O60674 | 2/20 | 0.86 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.86 |
| ▸ | LCK | P06239 | 2/20 | 0.86 |
| ▸ | FYN | P06241 | 2/20 | 0.86 |
| ▸ | FES | P07332 | 2/20 | 0.86 |
| ▸ | LYN | P07948 | 2/20 | 0.86 |
| ▸ | SRC | P12931 | 2/20 | 0.86 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.86 |
| ▸ | FER | P16591 | 2/20 | 0.86 |
| ▸ | MARK3 | P27448 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9998664 | 1.00 | AURKA (0.86) | AURKACDK2AURKBABL1NTRK1 | |
| SCHEMBL26184014 | 0.93 | AURKA (0.86) | AURKACDK2AURKBABL1NTRK1 | |
| SCHEMBL25277403 | 0.93 | AURKA (0.86) | AURKACDK2AURKBABL1NTRK1 | |
| Danusertib SCHEMBL2685432 | 0.92 | AURKA (1.00) | AURKACDK2AURKBABL1NTRK1 | |
| Danusertib SCHEMBL466509 | 0.92 | AURKA (1.00) | AURKACDK2AURKBABL1NTRK1 | |
| SCHEMBL1379851 | 0.92 | AURKA (0.85) | AURKACDK2AURKBABL1NTRK1 | |
| Danusertib SCHEMBL29453494 | 0.92 | AURKA (0.98) | AURKACDK2AURKBABL1NTRK1 | |
| SCHEMBL1377947 | 0.91 | AURKA (0.85) | AURKACDK2AURKBABL1NTRK1 | |
| SCHEMBL3486691 | 0.91 | AURKA (0.85) | AURKACDK2AURKBABL1NTRK1 | |
| SCHEMBL3486749 | 0.91 | AURKA (0.85) | AURKACDK2AURKBABL1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084455-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-12-27 | — | — | US | claimed |
| JP-4728232-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| EP-1644376-B1 | PYRROLO 3,4-c PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-09-08 | — | — | EP | claimed |
| US-20100035876-A1 | Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-02-11 | — | — | US | claimed |
| US-20100004359-A1 | POLYMERIZED (SUBSTITUTED IMIDAZOLIUM) FOR IMPROVED HANDLING PROPERTIES IN SILICA-REINFORCED RUBBER COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2010-01-07 | — | — | US | claimed |
| JP-2009513525-A | — | — | 2009-04-02 | — | — | JP | claimed |
| EP-2004180-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-24 | — | — | EP | claimed |
| WO-2007113212-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-11 | — | — | WO | claimed |
| US-7141568-B2 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-28 | — | — | US | claimed |
| EP-1644376-A1 | PYRROLO 3,4-c PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-04-12 | — | — | EP | claimed |
| US-20050032839-A1 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | claimed |
| WO-2005005427-A1 | PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-01-20 | — | — | WO | claimed |
| US-8084455-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-12-27 | — | — | US | disclosed |
| EP-1644376-B1 | PYRROLO 3,4-c PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-09-08 | — | — | EP | disclosed |
| US-20100035876-A1 | Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-02-11 | — | — | US | disclosed |
| US-20100004359-A1 | POLYMERIZED (SUBSTITUTED IMIDAZOLIUM) FOR IMPROVED HANDLING PROPERTIES IN SILICA-REINFORCED RUBBER COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2010-01-07 | — | — | US | disclosed |
| US-7141568-B2 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-28 | — | — | US | disclosed |
| EP-1644376-A1 | PYRROLO 3,4-c PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-04-12 | — | — | EP | disclosed |
| US-20050032839-A1 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | disclosed |
| WO-2005005427-A1 | PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032839-A1 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K3, MAP3K19, MAP3K9 | AURKA 350/4885CDK2 113/4885AURKB 440/4885 |
| US-20100035876-A1 | Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors | ABL1, LTK, ABL2 | AURKA 281/4885CDK2 454/4885AURKB 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.